Vir Biotechnology, Inc.VIREarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Vir Biotechnology, Inc. is a clinical-stage immunology company focused on developing innovative therapies and vaccines to address serious infectious diseases including COVID-19, hepatitis B, HIV, and influenza. It operates primarily in the global biopharmaceutical market, collaborating with leading industry partners to advance its pipeline of targeted immune-based solutions for patient populations worldwide.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 12.50% | 16.9M | — | 2024-01-23 |
| SVF | 12.40% | 16.7M | — | 2024-02-13 |
| The Vanguard Group | 9.14% | 12.3M | — | 2024-02-13 |
| STATE STREET CORPORATION | 4.10% | 5.6M | ▼ -1.04pp | 2024-10-18 |
Insider Transactions
Net 90d: −$2.16M · buys $0 / sells $2.16MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-06 | De Backer Marianne | President and CEO | Sell (open market) | 72.6K | $9.16 | $664.4K |
| 2026-04-01 | SATO VICKI L | Director | Sell (open market) | 22.0K | $9.07 | $199.6K |
| 2026-03-23 | Brent Sabatini | SVP, Chief Accounting Officer | Sell (open market) | 7.7K | $9.12 | $70.3K |
| 2026-03-20 | O'Byrne Jason | EVP & Chief Financial Officer | Other | 2.5K | $0.00 | $0 |
| 2026-03-20 | O'Byrne Jason | EVP & Chief Financial Officer | Other | 2.5K | $0.00 | $0 |
| 2026-03-02 | SATO VICKI L | Director | Sell (open market) | 21.8K | $9.50 | $207.2K |
| 2026-03-02 | SATO VICKI L | Director | Sell (open market) | 200 | $9.98 | $2.0K |
| 2026-02-25 | Mark Eisner | EVP and Chief Medical Officer | Sell (open market) | 1.9K | $9.82 | $18.5K |
| 2026-02-25 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | Sell (open market) | 13.7K | $9.82 | $134.5K |
| 2026-02-24 | SATO VICKI L | Director | Option exercise | 42.4K | $1.49 | $62.9K |
1–10 of 28
Page 1 / 3